We are pleased to announce that we are now adding the Eastpak brand to our product range. Eastpak is a renowned manufacturer of high-quality backpacks, bags and luggage.

Eastpak is characterized by its modern design, durable workmanship and innovative functions, which is why the brand is very synonymous with quality and reliability.

The products are available online as well as in our BMX shops in Stuttgart and Berlin and we are happy to be able to offer them to you from now on.

Best regards
Your kunstform BMX shop team

It has now been 20 years since Sebastian Pospischil registered the kunstform business and we celebrated this anniversary in style in our BMX shop in Stuttgart. Before the big party started in the shop, we threw a jam in our bike warehouse, which was an homage to our famous stock sessions. After the BMX action in the warehouse, we went straight to party mode on the upper floor of our shop in Stuttgart. The video of the stock session and party is now online. Give you!

Thank you Freedombmx for the video! Also thank you for your support; without you this anniversary would never have been possible. A big thank you also goes to our supporters for this event: @odysseybmx & @demolitionparts via @sibmxdistro, @shadowridinggear & @mankindbmx via @unitybmx, @fitbikeco & @sandmbicycles via @allridebmx, @cultcrew & @eclatbmxbrand via @traffic .bmx and @ridetsg via @247bike.

Stocks are reasonably priced and are a good place for ordinary folks' long-term savings.

An EU-BON Workshop focusing on the DINA system - "Alpha version of mobilization system – the DINA-system MS141" - was hosted the 16. to 18. September 2014 by the Swedish Museum of Natural History in Stockholm.

Target group: programmers, developers and system engineers, but the workshop was open to anybody who was interested to learn more about the DINA-system.

Content included:

• Presentations from all DINA-partners
• APIs, service oriented architecture and road map for distributed development, guidelines and principles on how to build a module and join the DINA-system
• Case studies
• Delivery options: creating installations from hosted environment, virtual machines down to source code

For program, particpants list, presentations etc please vist the DINA wiki

The EU is a party to the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilisation. The EU ABS Regulation1, which transposes into the EU legal order the compliance pillar of the Protocol, became applicable as of 12 October 2014. The principal obligations of the Regulation – i.e. Article 4 on due diligence, Article 7 on monitoring user compliance and Article 9 on checks on user compliance – will become applicable as of 12 October 2015.

In this context it is important that those who utilise genetic resources (i.e. conduct research and development on the genetic and/or biological composition of genetic resources, including through the application of biotechnology) are aware of the obligations arising from the Regulation, and that they can take the necessary measures to ensure their activities are compliant.

What's in it for you?

The EU ABS Regulation workshop aims at providing the participants with knowledge about their obligations under the EU ABS Regulation and what they practically imply for their everyday work. In the first part of the workshop, the new legal framework will be explained, providing insight into the main provisions of the EU ABS Regulation. In the second part of the workshop, participants will have a chance to put the knowledge gained into practice through interactive case studies, based on real-life examples and realistic scenarios.

The workshop should allow participants to better understand their obligations under the EU law, and to establish which steps they need to follow and which practical measures they should take when dealing with genetic resources originating from Parties to the Nagoya Protocol.

Planning and location of the workshops: 

Feel free to apply for registration to one of the following workshops:

• 18 October: Stockholm
• 17 November: Warsaw
• 21 November: Leiden
• Date to be determined: Budapest

The workshop is targeted at senior academics and experienced researchers conducting research and development on genetic resources who have an interest in gaining an essential understanding of the new legal framework in the EU, in view of the ABS Regulation becoming fully operational later this year.

Registration page: http://www.euconf.eu/abs/en/registration/index.html

The EU ABS Regulation workshop aims at providing the participants with knowledge about their obligations under the EU ABS Regulation and what they practically imply for their everyday work. In the first part of the workshop, the new legal framework will be explained, providing insight into the main provisions of the EU ABS Regulation. In the second part of the workshop, participants will have a chance to put the knowledge gained into practice through interactive case studies, based on real-life examples and realistic scenarios.

Registration page: http://www.euconf.eu/abs/en/registration/index.html

Trump has pledged to make the country “the crypto capital of the planet” and create a “strategic reserve” of bitcoin.

The post Stocks and bitcoin soar after Trump’s victory, while inflation worries rise; Dow surges 1,200 appeared first on Boston.com.

On Sept. 17, JLG introduced new features for its ES electric scissor lifts, E18 vertical lifts and E18 stock picker, including standard AC drive motors, lithium-ion battery options and a range-extending genset charging option.

Washington — A new OSHA safety alert lists measures employers should take to protect stockroom and loading dock workers during the ongoing COVID-19 pandemic.

Arlington, VA – The Mine Safety and Health Administration has released a safety alert in response to seven stockpile incidents involving dozers in 2015.

Washington — The Federal Motor Carrier Safety Administration is seeking comment on a petition that aims to amend hours-of-service requirements for haulers of livestock, insects and aquatic animals, allowing for a 16-hour on-duty period after 10 consecutive hours of off-duty time, the agency announced in the Feb. 6 Federal Register.

Washington — Sens. John Hoeven (R-ND) and Michael Bennet (D-CO) have reintroduced bipartisan legislation that would require the secretary of transportation to create a working group to determine obstacles to safe operation for livestock, insect and agricultural haulers in an effort to reform federal hours-of-service and electronic logging device regulations.

Washington – Bipartisan bills introduced in the House on March 12 would exempt certain segments of the commercial motor vehicle industry from the Federal Motor Carrier Safety Administration’s mandate on use of electronic logging devices to record truck driver hours of service.

Washington — Stakeholders in the commercial trucking and livestock industries are applauding a provision to the Infrastructure Investment and Jobs Act that gives livestock and insect haulers an additional exemption from Federal Motor Carrier Safety Administration hours-of-service regulations.

Washington – NIOSH is seeking information from facilities that stockpile N95 respirators and high-level protective surgical gowns as part of a research study that will examine how storage conditions affect the deterioration of personal protective equipment.

Farm animals can present real dangers to farmers, ranchers and their families.

Kitchen Basics® has a portfolio of conventional and organic stocks and broths, including Chicken, Unsalted Chicken, Beef, Unsalted Beef, Vegetable, Unsalted Vegetable, Turkey, Seafood, and Creamy Bean & Vegetable.

Warren Buffett is now sitting on more than $325 billion cash after continuing to unload billions of dollars worth of Apple and Bank of America shares this year and continuing to collect a steady stream of profits from all of Berkshire Hathaway’s assorted businesses without finding any major acquisitions.

[Economy] :
Foreign investors were net sellers in the South Korean stock market for the third month in October. According to data from the Bank of Korea(BOK) on Friday, foreigners sold a net four-point-17 billion U.S. dollars worth of stocks last month. But the latest figure is lower than September’s total of ...

[more...]

Michael Ballanger of GGM Advisory Inc. shares his thoughts on the silver market and shares one copper stock he believes is a Strong Speculative Buy even though the stock is currently halted.

Source: Dr. Joseph Pantginis 11/04/2024

H.C. Wainwright & Co. analysts Dr. Joseph Pantginis, Dr. Lander Egaña Gorroño, Dr. Joshua Korsen, Dr. Matthew Keller, and Dr. Sara Nik, in a research report published on November 4, 2024, maintained their Buy rating on Lexicon Pharmaceuticals Inc. (LXRX:NASDAQ) with a price target of US$6.00. The report follows Lexicon's presentation of preclinical data for LX9851, its ACSL5 inhibitor for obesity, at ObesityWeek 2024.

The analysts highlighted key findings from the presentations, stating, "LX9851 promotes reduction of fat mass without affecting lean body mass" and "LX9851 improves and sustains GLP-1 RA-mediated weight loss, even after semaglutide discontinuation." They added that "Mechanistic studies suggest that LX9851-mediated ACSL5 inhibition activates the ileal brake."

Regarding the drug's potential, they noted, "LX9851 is a first-in-class, oral small molecule ACSL5 inhibitor designed to enhance and maintain weight loss promoted by incretin mimetics (GLP-1 receptor agonists), and offer improved treatment alternatives for obesity and related metabolic disorders."

The report also addressed recent developments with sotagliflozin, detailing the AdCom voting results and potential scenarios for FDA action. The analysts stated, "Although we anticipate favorable feedback from the agency regarding eGFR ≥60 to <90 range, our bet is that a confirmatory trial may be required to validate sota's efficacy in this subpopulation and obtain approval."

H.C. Wainwright & Co.'s valuation methodology is based on a clinical net present value (NPV) model. The analysts explained, "Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug's profile. We currently value Lexicon solely on sotagliflozin sales in the U.S. for HF (INPEFA), HCM, and LX9211 for DPNP."

They added, "We believe significant upside potential exists, based on: (1) attaining higher market penetration for HF, and HCM; and (2) adding the earlier stage assets."

In conclusion, H.C. Wainwright & Co.'s maintenance of their Buy rating and US$6 price target reflects confidence in Lexicon's pipeline potential, particularly with LX9851 and sotagliflozin. The share price at the time of the report of US$1.22 represents a potential return of approximately 392% to the analysts' target price, highlighting the significant upside potential if the company's development programs prove successful.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co., Lexicon Pharmaceuticals Inc., November 4, 2024

This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet. H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Joseph Pantginis, Ph.D., Lander Egaña Gorroño, Ph.D., Joshua Korsen, Ph.D., Matthew Keller, Ph.D. and Sara Nik, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of Lexicon Pharmaceuticals, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of September 30, 2024 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Lexicon Pharmaceuticals, Inc..

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The firm or its affiliates received compensation from Lexicon Pharmaceuticals, Inc. for non-investment banking services in the previous 12 months. The Firm or its affiliates did not receive compensation from Lexicon Pharmaceuticals, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in Lexicon Pharmaceuticals, Inc. as of the date of this research report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

( Companies Mentioned: LXRX:NASDAQ, )

Satisfy your customers and win in the stock market, says a new study by a team of researchers from Michigan's University Research Corridor, who found positive stock returns on customer satisfaction far out-distance competitive market measures that have been in play for more than half a century.

read more

We keep super glue on the truck for any time we run into needing an O-ring, but don't have the exact size. 

Amcor unveiled its latest innovation: a 1-liter PET bottle for carbonated soft drink (CSD) use that is made from 100% post-consumer recycled (PCR) content.

Attorney Matthew Wolper explains the four most common types of stockbroker fraud.

A Stunning Blend of Comfort and Elegance Awaits in Woodstock, IL's Premier Luxury Estate - An Exceptional Opportunity with a Highly Attractive Assumable Loan

Content producers browse talent and find exactly who they need using unique search tools.

Ackerman Retail's Brian Lefkoff and Stephany Cruz represent luxury patisserie in its first location outside of Louisiana

Oaks to manage Camellia Place beginning March 2024

ShorrExpress® Product Line Hedges Supply Chain Disruptions, Bringing to Market Affordable, Available, and Quality Packaging Supplies

Pad-mounted transformer inventory for bitcoin mining

The Paraguayan company ICP S.A. (short for Industrias Citrícolas de Paraguay) is in the middle of the approval process for its initial public offering in Paraguay.

Join us at Jio World Convention Centre, Mumbai, India, on August 17-18, 2024

Groundbreaking app transforms stock chart movements into real-time music, offering an accessible and innovative tool for traders, especially those with visual impairments.